Abstract
Introduction With the economic recession and pandemic fatigue, milder viral variants and higher vaccine coverage along the time lay the basis for lifting anti-COVID policies to restore COVID-19 normalcy. However, when and how to adjust the anti-COVID policies remain under debate in many countries.
Methods In this study, four countries (Singapore, South Korea, Australia, and New Zealand) and one region (Hong Kong SAR), that have shifted from the zero-COVID (ZC) policy to or close to the living-with-COVID (LWC) during or after the Omicron outbreak, were selected as research objects. All-cause mortality data were collected for these objects from 2009-2019. The expected mortality was estimated by a simple linear regression method. Excess mortality over time was calculated as the difference between the expected mortality and the observed mortality. Finally, percent excess mortality (PEM) was calculated as the excess mortality divided by the expected mortality.
Results In the examined four countries, PEM fluctuated around 0% and was lower than 10% most of the time under the ZC policy before 2022. After shifting to the LWC policy, all the examined countries increased the PEM. Briefly, countries with high population density (Singapore and South Korea) experienced an average PEM of 20-40% during the first half of 2022, and followed by a lower average PEM of 15-18% during the second half of 2022. For countries with low population density under the LWC policy, Australia experienced an average PEM of 39.85% during the first half of 2022, while New Zealand was the only country in our analysis that achieved no more than 10% in average PEM all the time. On the contrary, Hong Kong SAR under their ZC policy attained an average PEM of 71.14% during the first half of 2022, while its average PEM decreased to 9.19% in the second half of 2022 with LWC-like policy.
Conclusion PEM under different policies within each country/region overtime demonstrated that the mortality burden caused by COVID-19 had been reduced overtime. Moreover, anti-COVID policies are suggested to control the excess mortality to achieve as low as 10% in PEM.
Contribution to the field
This study compared excess mortality within the same country/region, instead of among countries, thus, PEM during the outbreaks of different SARS-cov-2 variants overtime could reflect the effectiveness of regional specific anti-pandemic policies in protecting the lives of citizens locally.
Our analysis demonstrated that Singapore, South Korea and Australia might implement the LWC policy without sufficient preparation, which resulted in a very high mortality burden during the first half of 2022.
The reduced PEM in late 2022 in the examined countries/regions suggested that the mortality burden caused by COVID-19 was reduced overtime, laying a great foundation to call for a further relief of LWC policy in the world in the near future.
This study delineated a threshold of percent excess mortality, which is 10%, as a criterion to assess the effectiveness of anti-COVID policies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by PolyU Internal Funding (#P0030234) to Yuyan Zhu, and the start-up fund of Hong Kong University of Science and Technology (Guangzhou) (# G0101000092) to Yulong Zi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://tablebuilder.singstat.gov.sg/table/TS/M810121 https://news.google.com/covid19/map?hl=en-US&gl=US&ceid=US%3Aen https://mpidr.shinyapps.io/stmortality https://www.censtatd.gov.hk/en/EIndexbySubject.html?pcode=B1010002&scode=460
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have updated the mortality data and its associated PEM values based on the new data released recently. Specifically, we have updated data from March 2022-September 2022 for Singapore, from week 17, 2022 to week 39, 2022 for South Korea, from week 12, 2022 to week 30, 2022 for Australia, from week 24, 2022 to week 43, 2022 for New Zealand, from April 2022 to September 2022 for Hong Kong. With these recent data, we have updated our results and conclusions accordingly.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- PEM
- Percent excess mortality
- PCEM
- Percent COVID-excess mortality
- ZC
- Zero-COVID
- LWC
- Living-with COVID